Faeth Therapeutics, Inc. FTH
12.92 USD +0.24 (+1.89%)
At closeNov 11, 2026, 4:24 AM EST
12.77 -0.15 -1.19%
Pre-market · Nov 11, 4:24 AM ET
11.83 Day range 13.93
7.45 52-week range 42.14
- YTD
- +21.09%
- 1 year
- +34.44%
News
benzinga.com Citigroup Maintains Buy on Faeth Therapeutics, Raises Price Target to $60 Citigroup analyst Geoff Meacham maintains Faeth Therapeutics (NASDAQ:FTH) with a Buy and raises the price target from $55 to $60.
benzinga.com Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results U.S. stocks surged Monday, led by a 2.1% S&P 500 gain; NRG jumped on strong results, while Zura Bio plunged 75% after trial failures.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com Dow Jumps Over 600 Points; Constellation Energy Posts Upbeat Earnings U.S. stocks rallied Monday, led by tech and consumer discretionary shares. Constellation Energy beat Q3 estimates; oil fell while gold rose.
benzinga.com Faeth Therapeutics Announces Data From Its Phase 2 Study Of PIKTOR Shows Confirmed Objective Response Rate OF 33%, Disease Control Rate Of 83% Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced topline clinical data from…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million. Vir Biotechnology (NASDAQ:VIR)…
businesswire.com Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
benzinga.com Why Greenfire Resources Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket Greenfire shares surged 25% after Strathcona announced a C$2.7B-C$2.9B acquisition; several small-cap stocks posted sharp premarket gains and losses.- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million. Nkarta (NASDAQ:NKTX) stock…
benzinga.com Faeth Therapeutics To Conduct Virtual Event On Nov. 9 To Present Topline Data From Its Phase 2 PIK-2-1 Study Of PIKTOR To Treat Endometrial Cancer Faeth Therapeutics (NASDAQ:FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a…
businesswire.com Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026 AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
businesswire.com Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an…
benzinga.com Guggenheim Maintains Buy on Faeth Therapeutics, Lowers Price Target to $69 Guggenheim analyst Michael Schmidt maintains Faeth Therapeutics (NASDAQ:FTH) with a Buy and lowers the price target from $70 to $69.
benzinga.com Faeth Therapeutics Q3 EPS $(0.79) Misses $(0.71) Estimate Faeth Therapeutics (NASDAQ:FTH) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.71) by 11.27 percent. This is a 78.18 percent increase over losses of…- benzinga.com BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target BTIG analyst Jeet Mukherjee reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $55 price target.
benzinga.com William Blair Initiates Coverage On Faeth Therapeutics with Outperform Rating William Blair analyst Alethia Young initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating.